Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Structural chromosome rearrangements may result in the exchange of coding or regulatory
DNA sequences between genes. Many such gene fusions are strong driver mutations in …

Osimertinib has been demonstrated to overcome the epidermal growth factor receptor
(EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine …

Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET)
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …

Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes
were recently identified as new targetable genetic aberrations in cases of non-small cell …

Lung adenocarcinoma (LADC), the most frequent histological type of lung cancer, is often
triggered by an aberration in a driver oncogene in tumor cells. Examples of such aberrations …

RET receptor tyrosine kinase is activated in various cancers (lung, thyroid, colon and
pancreatic, among others) through oncogenic fusions or gain-of-function single-nucleotide …

Cancer is a disease largely caused by genomic aberrations. Utilizing many rapidly emerging
sequencing technologies, researchers have studied cancer genomes to understand the …

Purpose: To identify druggable oncogenic fusions in invasive mucinous adenocarcinoma
(IMA) of the lung, a malignant type of lung adenocarcinoma in which KRAS mutations …

Background Pulmonary ground-glass nodules (GGNs) include both malignant and benign
lesions. Some GGNs become larger, whereas others remain unchanged for years. We have …